Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed) | RFA-AI-24-017 | NIAID | The purpose of this notice of funding opportunity (NOFO) is to support research that 1) defines associations between variations in human leukocyte antigen (HLA) and killer cell immunoglobulin-like… More | ||
| NIAID Research Education Program (R25 Clinical Trial Not Allowed) | PAR-22-134 | NIAID | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this National Institute of Allergy and infectious Diseases (… More | ||
| Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed) | RFA-AI-24-025 | NIAID | The purpose of this Notice of Funding Opportunity (NOFO) is to support basic and applied research to understand and improve durable immune responses to candidate HIV vaccines. | ||
| Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) | PAR-23-180 | NIAID | The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic)… More | ||
| Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed) | PAR-22-223 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-… More | ||
| Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | PAR-22-186 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological… More | ||
| Notice of Special Interest (NOSI): Competitive Revision Supplements to Existing T32 Programs to Include Institutional Research Training in Data Science for Infectious and Immune Mediated Diseases | NOT-AI-24-012 | NIAID | This Notice of Special Interest (NOSI) solicits competitive revision applications to support the expansion of existing National Institute of Allergy and Infectious Diseases (NIAID) T32 programs. This… More | ||
| NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) | PAR-22-075 | NIAID | The purpose of the NIAID Career Transition Award (CTA) program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful… More | ||
| Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed) | PAR-22-185 | NIAID | The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and… More | ||
| Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | PAR-23-033 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product… More |